http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020061486-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a8470f22066c0ba2fe50741174c7ab
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
filingDate 2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e352f61192d0fdf438d7f86ec8a8d3f7
publicationDate 2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2020061486-A3
titleOfInvention Dosage forms and methods for enantiomerically enriched or pure bupropion
abstract This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
priorityDate 2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0162257-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012118562-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226424248
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419575387
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID667684
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419532742
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444

Total number of triples: 20.